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ABSTRACT Bullous pemphigoid (BP) is an autoimmune disorder which 
is usually chronic, with blistering that predominantly affects the skin 
and occasionally the mucosa, and which includes several different types. 
One of them is a very rare dyshidrosiform type which is localized on the 
hands and feet with small or large blisters on the palmoplantar surfaces. 
BP resulting from a drug reaction is a relatively rare occurrence, and so 
far more than 50 different medications have been identified as triggers. 
The aim of this article was to present the case of a paraplegic patient 
who developed this rare dyshidrosiform type of BP while he was being 
neurologically treated with baclofen. In spite of therapy with systemic 
and topical corticosteroids and other measures, successful treatment 
was achieved only after eliminating baclofen from the patient’s regi-
men. His general state of health was seriously endangered due to nasal 
and skin methicillin-resistant Staphylococcus aureus (MRSA), urinary in-
fection, and oral mycosis (soor), and he was at high risk of sepsis and a 
fatal outcome. Through our efforts, however, we managed to achieve an 
excellent outcome. According to our knowledge, this was the first case 
of baclofen-induced dyshidrosiform BP.
KEY WORDS: bullous pemphigoid, baclofen, dyshidrosiform pemphi-
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INTRODUCTION
Bullous pemphigoid (BP) is a usually chronic au-
toimmune disorder with blistering that predomi-
nantly affects the skin and sometimes the mucosa 
(1-3). There are several variants, including the rarer 
dyshidrosiform type. It can clinically resemble com-
mon dyshidrosiform dermatitis, manifesting as small 
or large blisters on palmoplantar surfaces. These sub-
epidermal blisters appear as a result of IgG autoanti-
bodies binding to transmembrane hemidezmosomes 
via a 230 kDa plakin molecule (1-4). Currently, there is 
Received: January 23, 2018
Accepted: May 14, 2019
ACTA DERMATOVENEROLOGICA CROATICA184
185
Lugović-Mihić et al. Acta Dermatovenerol Croat
Baclofen-induced dyshidrosiform BP     2019;27(3):184-187
little data on etiological factors of this very rare type 
of BP. 
The diagnosis of BP is based on clinical and his-
tologic findings, immunofluorescent characteristics, 
serum antibodies, etc. (1,3,5-10). There are a few re-
lated diseases observed in patients with BP such as 
neurological disorders and internal malignancies. 
Previous research has reported a greater frequency 
of BP among patients with neurological disorders 
such as Parkinson’s disease, epilepsy, multiple scle-
rosis, cerebrovascular disease, dementia, dyskinesia, 
etc. (4,6-8). 
We present the case of a paraplegic patient who 
developed the rare dyshidrosiform type of BP while 
he was being treated with baclofen, a medication 
with spasmolytic effects on the central nervous sys-
tem. To our knowledge, there is no previously re-
corded case of a connection between dyshidrosiform 
pemphigoid and baclofen.
CASE REPORT
A white 49-year-old male paraplegic patient was 
admitted to our clinic due to skin lesions – various-
sized blisters on the erythematous surfaces of the 
palms and soles of the feet and mild oral lesions (Fig-
ure 1, Figure 2) which he had noticed ten days before 
being admitted. Prior to his arrival he had been treat-
ed by his local dermatologist with parenteral system-
ic corticosteroids, peroral antibiotics (amoxicillin and 
clavulanic acid) and topical antiseptics, but without 
success. 
Over the previous 4 years, the patient had been 
suffering paraplegia of the distal extremities and uri-
nary incontinence as a result of spinal cord lesions 
(ischemic transversal myelitis with a possible inflam-
matory etiology). His neurologist prescribed baclofen 
tablets, which the patient started taking two years 
before admission to our clinic. Additionally, before we 
saw him, the patient had undergone urologic ileocys-
toplasty a year earlier and had since been practicing 
intermittent self-catheterization through a cystos-
tomy. 
Extensive workup was performed during hospital-
ization, including a lesional skin biopsy which showed 
histologic characteristics of BP (Figure 3), while direct 
immunofluorescence (DIF) showed linear deposits of 
IgG and C3 in the basement membrane zone. Serum 
tests were also performed: the BP180 antigen was 
positive (149.0 U), BP230 was negative, and DSG-1 
and DSG-3 were also negative (ELISA).
Based on these findings (histopathology, DIF, 
BPAGs), we established the diagnosis of BP and con-
cluded it was specifically dyshidrosiform BP due to 
the appearance of dyshidrosiform skin lesions. Being 
the probable trigger, baclofen was gradually discon-
tinued in consultation with a clinical pharmacologist 
and neurologist. Perioral low-dose diazepam was 
thus introduced instead.
Nasal and skin swabs were taken as part of our 
workup, and methicillin-resistant Staphylococcus au-
reus (MRSA) was isolated in both samples, showing 
heavy bacterial growth. Since it was mupirocine-re-
sistant, a topical skin treatment with chlorhexidine 
solution was used. Octenidine was used for nasal 
decolonization over 5 days. The patient was treated 
under special conditions and in isolation. After topi-
cal treatment, control swabs showed eradication of 
MRSA. Urine cultures revealed Pseudomonas aerugi-
nosa (≥106 CFU/mL), which we treated with ceftazi-
dime and cefepime. In a second urine culture, Entero-
coccus spp. (≥106 CFU/mL) was isolated and conse-
quently treated (amoxicillin and nitrofurantoin).
The patient was also treated parenterally and 
perorally with systemic corticosteroids (40 mg of 
Figure 1. Blisters, erosions, and crusts on the hands. Figure 2. Blisters, erosions, and crusts on the feet.
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methylprednisolone daily with gradual dose taper-
ing), systemic antihistamines, and azathioprine (100 
mg daily). Topical corticosteroid and antibiotic treat-
ments were also applied to skin lesions. He also re-
ceived anticoagulation therapy (low-molecular war-
farin) due to paraplegia and a pulmonary embolism 
incident 4 years earlier. The patient was also under 
neurological and urological supervision, and gas-
troenterological and proctologic workups were per-
formed because of gastrointestinal discomfort. The 
patient was also examined by an oral pathologist 
who observed desquamative gingivitis. Because of 
oral mycosis (soor), confirmed by isolation of Candida 
spp. from a tongue swab, an antimycotic treatment 
and antiseptic oral solution were recommended. 
When therapy resulted in regression of skin lesions 
and epithelization at sites of erosion, the patient was 
discharged and continued therapy at home (24 mg 
of peroral methylprednisolone daily with subsequent 
gradual dose tapering; 100 mg of azathioprine daily 
as a topical therapy).
Five years later, the patient reported feeling well 
with no signs of relapse. 
DISCUSSION
Apart from typical BP presentation, there are a 
number of clinically distinct BP variants (gestational, 
infantile, vegetans, nodularis, vesicular, papular, ec-
zematous, erythrodermic, lichen planus pemphigoid, 
purpuric, and dyshidrosiform) (1,3,11-13). Dyshidrosi-
form pemphigoid is rare, but this subtype should be 
specifically identified when it does occur (14-16). 
However, all BP types are based on the basic 
pathophysiological mechanism of autoantibodies 
binding to hemidesmosomal proteins of the dermo-
epidermal junction: BP antigen 180 (BPAg2 or type 
XVII collagen) and BP antigen 230 (BPAg1e). Although 
BP is mostly a disease of the elderly (onset usually oc-
curs after age 60), it can also appear at a somewhat 
earlier age, as was the case with our patient (1,13). 
The association of BP with medical conditions such 
as neurological diseases is probably due to a patient’s 
advanced age rather than to BP itself (3,4). It should 
be noted that there is a similarity between BP230 
(dystonin) and BPAg1 which may cause autoantibod-
ies to react similarly, thus possibly explaining the 
connection between neuroautoimmunity and the 
autoimmune response in the pemphigoid group 
(17). Furthermore, special variants of BP230 are also 
expressed throughout the central and peripheral ner-
vous system (3). Although the association between BP 
and neurologic diseases has been well documented, 
their exact pathogenic relationship is yet to be eluci-
dated (4,7,8).
BP as a result of a drug reaction is a relatively rare 
occurrence. However, more than 50 different medi-
cations have been described as triggers so far, with 
the number rising further (18,19). Since testing our 
patient was not possible, we still do not have diag-
nostic confirmation that baclofen was the trigger 
for disease development; however, the patient was 
previously treated with systemic corticosteroids, and 
only after discontinuation of baclofen did we observe 
long-term lesion resolution, confirming that baclofen 
was the trigger. Testing can result in false negatives 
even when it is performed, and adverse reactions 
sometimes have etiologies which cannot be discov-
ered by tests but only by discontinuing a medication 
or by process of elimination.
As of this writing, no reports of similar cases were 
found in which baclofen was the possible trigger of BP, 
as described in our case study. Furthermore, according 
to the PubMed/MEDLINE database, the total number 
of published articles retrieved with the key words “dys-
hidrosiform pemphigoid” does not exceed 26.
Fatal outcomes are common in patients with se-
vere general skin conditions such as BP, as described 
by other authors (12,20). A crucial factor for achieving 
a good outcome is the exclusion of the causative agent 
– in this case a drug, supported by administration of 
systemic and topical corticosteroids or other immu-
nosuppressive therapies such as azathioprine or even 
dapsone (1,13). However, special caution is needed 
with patients receiving a high dosage or long-term 
immunosuppressive therapy because of the high risk 
Figure 3. A biopsy specimen from the left hand showed 
focal spongiosis in the epidermis (thin arrow; hematoxylin 
and eosin ×40).
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of sepsis or other complications. Therefore, adequate 
recognition and treatment of infection, including po-
tentially life-threatening pathogens such as MRSA, is 
essential, as is the prevention of other complications 
(e.g. thrombosis). It is especially important to achieve 
a long-term stable condition for the patient, and they 
can only be declared disease-free after a longer pe-
riod of monitoring.
CONCLUSION
Given that the dyshidrosiform variant of pem-
phigoid is a rare occurrence within the pemphigoid 
group, more research is needed to establish an as-
sociation between it and various factors, including 
medications such as baclofen.
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